The price of Revelation Biosciences Inc. (NASDAQ:REVB) shares last traded on Wall Street unchanged to $1.63.
REVB stock price is now -70.24% away from the 50-day moving average and -87.11% away from the 200-day moving average. The market capitalization of the company currently stands at $1.12M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
A total of 59.18% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in REVB stock. A new stake in Revelation Biosciences Inc. shares was purchased by REBALANCE, LLC during the first quarter worth $4,000. In total, there are 16 active investors with 18.50% ownership of the company’s stock.
A candlestick chart of Revelation Biosciences Inc. (NASDAQ: REVB) showed a price of $1.5800 on Thursday morning. During the past 12 months, Revelation Biosciences Inc. has had a low of $1.55 and a high of $100.80. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.50, and a quick ratio of 1.50. The fifty day moving average price for REVB is $5.4797 and a two-hundred day moving average price translates $12.6455 for the stock.
The latest earnings results from Revelation Biosciences Inc. (NASDAQ: REVB) was released for Sep, 2022.
Revelation Biosciences Inc.(REVB) Company Profile
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Leave a Reply